timothy sykes logo
Exact Sciences Soars Amid Takeover Talks by Abbott Thumbnail
ADD US ONG Google News

Exact Sciences Soars Amid Takeover Talks by Abbott

BRYCE TUOHEY•UPDATED NOV. 20, 2025, 11:33 AM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

Exact Sciences Corporation’s stock surges 17.53% fueled by positive news indicating significant advancements in cancer screening technology.

Candlestick Chart

Live Update At 11:33:21 EST: On Thursday, November 20, 2025 Exact Sciences Corporation stock [NASDAQ: EXAS] is trending up by 17.53%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Exact Sciences has recently been making waves with its promising technological advancements and strategically beneficial partnerships. On the stock chart, a significant jump in the price is evident, reflecting investor excitement over the company’s potential acquisition. Daily trading data showcases a meteoric rise from $69.5 to a whopping $101.29 per share, following the buzz surrounding the acquisition talks with Abbott Laboratories.

In terms of key financial metrics, the company showcases a strong gross margin of 68.2%, indicative of its efficient product offerings and competitive pricing strategies. However, challenges loom with negative profitability ratios, such as an EBIT margin of -33.7% and a profit margin of -34.19%, underscoring ongoing operational hurdles.

Revenue Insights:
With a total revenue reported at $2.76B for the recent period, Exact Sciences continues its growth trajectory, albeit with room for enhancement in operational efficiency. A per-share revenue of $14.56 suggests solid earning potential, even as market scale broadens.

Valuation and Performance:
The company’s enterprise value stands at approximately $17.85B, indicating robust market expectations. Yet, the lack of a P/E ratio highlights its persistent net income challenges—a contrast to conventional profitability benchmarks.

Investment Dynamics:
Exact Sciences displays a price-to-sales ratio of 4.49, and its leverage remains manageable with a total debt to equity of 1.02, demonstrating prudent financial management amid expansive growth pursuits. The quick and current ratios support a healthy liquidity position, reinforcing its capacity to handle short-term obligations.

Proposed Acquisition: Potential Gateway for Growth

The recent buzz about Abbott Laboratories’ intention to acquire Exact Sciences has not only lifted its stock price by 26% but also sparked talk among investors about a transformative shift in the cancer diagnostics market. This potential takeover could mark a pivotal moment, as it integrates Exact Sciences’ innovative technologies within Abbott’s expansive reach.

Abbott’s interest seems driven by Exact Sciences’ recent achievements in cancer screening advancements, prominently their groundbreaking Oncoguard Liver test. This new blood test detects liver cancer stages significantly earlier than the traditional ultrasound method, holding promise for enhanced patient outcomes.

Financial Implications:
The anticipation surrounding the acquisition deal has shifted market expectations, leading to speculation on an acquisition price exceeding $100 per share. Analysts predict that such a deal could bring significant premiums, elevating Exact Sciences’ valuation to new heights.

More Breaking News

For stakeholders, this merger presents an opportunity for maximizing shareholder value while securing a strong footing in global health solutions, fostering a more integrated approach to life-saving diagnostics.

Strategic Alliances and Technological Innovation

Further fortifying its competitive edge, Exact Sciences has concluded the waiting period for a key license agreement for Freenome’s blood-based colorectal cancer tests. With FDA approval, this licensing move solidifies its leadership in non-invasive cancer detection. The portfolio’s expansion is seen as a substantial milestone in its overarching strategy to revolutionize cancer diagnostics.

Additionally, the ALTUS study’s findings effectively raised Exact Sciences’ profile, showcasing superior detection rates for early-stage liver cancer—a testament to its cutting-edge capabilities. This bolstered its stock price, as investors bank on therapeutic innovations that promise both improved health outcomes and fiscal returns.

Conclusion

Exact Sciences stands at the brink of a transformative period—an era marked by scientific innovation, strategic expansion, and possible integration with industry giant Abbott Laboratories. The latest takeover news has sparked trader optimism, reflected in the significant price surge.

Moving forward, Exact Sciences is poised to redefine its market positioning, leveraging novel cancer detection technologies and strategic partnerships. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” While profitability hurdles remain, its strategic ventures hold potential for greater revenue streams and market dominance. As the landscape shifts, stakeholders will keenly observe the unfolding developments, potentially entering a rich chapter of growth and innovation for Exact Sciences.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading EXAS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”